Age

30–75

Sex

FEMALE

Healthy volunteers

Not accepted

Female patients aged 30 to 75 years.
Histologically confirmed breast cancer.
Planned treatment with anthracycline- and/or trastuzumab-based chemotherapy.
High or very high risk of chemotherapy-induced cardiotoxicity (≥20%), based on clinical assessment.
Eastern Cooperative Oncology Group (ECOG) performance status 0-3.
Ability to take oral study products.
Willingness to comply with study procedures and follow-up visits.
Written informed consent provided prior to any study procedures.

ECOG performance status of 4.
Pre-existing severe cardiovascular disease that would interfere with study participation.
Permanent atrial fibrillation or other clinically significant arrhythmias.
Severe hepatic or renal impairment.
Active central nervous system tumors or metastases.
Uncontrolled arterial hypertension.
Acute gastrointestinal diseases that may impair absorption.
Known allergy or intolerance to grape products or study components.
Participation in another interventional clinical trial that may interfere with the outcomes of this study.

Grape Polyphenols for Prevention of Chemotherapy-Induced Cardiotoxicity